[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637203":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":32,"responsibleParty":51,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":25,"overallStatus":35,"whyStopped":25,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University of Rochester","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard-of-care Group","ACTIVE_COMPARATOR","Participants in this group will receive echocardiogram imaging before cycles 1, 5, 9, and 13 of trastuzumab (or every 3 months) and another echocardiogram after completion of trastuzumab (within 100 days after completion of HER2-TT).",[13],"Procedure: Echocardiogram",{"label":15,"type":16,"description":17,"interventionNames":18},"Judicious-imaging Group","EXPERIMENTAL","The Judicious Imaging Group will get split into two separate subgroups, intermediate-risk or low-risk, depending on their risk of heart failure, which will determine how many echocardiograms they will receive. The low-risk subgroup will get an echocardiogram once every 6 months (before cycles 1 and 9 and after the completion of trastuzumab). The intermediate-risk subgroup will get an echocardiogram approximately once every 4 months (before cycles 1, 6, and 12 and after completion of trastuzumab).",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Echocardiogram","12-lead echocardiogram",[15,9],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Kaily LaForce","CONTACT","585-274-2808","kaily_laforce@urmc.rochester.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Wilmot Cancer Center","RECRUITING","Rochester","New York","14642","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-77.61556,43.15478,{"lat":45,"lon":44},[48],{"name":49,"role":50,"phone":25,"phoneExt":25,"email":25},"Farhan Bajwa, MD, FACC","PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Farhan Bajwa","Assistant Professor","100637203","optimization-of-cardiac-imaging-in-women-with-early-stage-breast-cancer-100637203",false,"NCT07630402","Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer","Pilot Study for Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer","POCEB","Inclusion Criteria:\n\n* Female sex, age 18-79 years.\n* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT\n* Baseline LVEF ≥ 55 % by 2-D echocardiography.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Prior HF, myocardial infarction, or cardiomyopathy.\n* Atrial fibrillation or significant valvular heart disease.\n* Cumulative anthracycline dose ≥ 250 mg\u002Fm².\n* Pregnancy or lactation.\n* Inability to comply with study procedures.","FEMALE","18 Years","79 Years",{"count":66,"type":67},20,"ESTIMATED","INTERVENTIONAL",[70],"NA","The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).",[73],"Breast Cancer With Low to Intermediate HER2 Expression","2026-06-01",{"date":76,"type":77},"2026-06-05","ACTUAL",{"date":79,"type":77},"2025-11-17",{"date":81,"type":67},"2031-06-30",{"name":5,"class":6},1]